# A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

> **NCT03653026** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 522 (actual)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** Placebo
- **DRUG:** Upadacitinib

## Key facts

- **NCT ID:** NCT03653026
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-06
- **Primary completion:** 2021-01-14
- **Final completion:** 2021-01-14
- **Target enrollment:** 522 (ACTUAL)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03653026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03653026, "A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03653026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*